Dr. Patricia Davis -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Patricia Davis, a Oncology physician based in Dallas, TX. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Patricia Davis has received $23,865.50 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Patricia Davis has received a total of $23,865.50 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $23,865.50 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Patricia Davis's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Speaking & Education$23,865.50Promotional speaking, CME events, and educational presentations

The largest payment category for Dr. Patricia Davis is Speaking & Education, accounting for 100% ($23,865.50) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Patricia Davis. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Roche/Genentech$23,865.501

Dr. Patricia Davis has a financial relationship with Roche/Genentech, receiving $23,865.50 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Patricia Davis's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Patricia Davis has received $23.9K across 1 pharmaceutical payments as a Oncology physician in Dallas, TX. Top paying companies include Roche/Genentech ($23.9K). Dr. Davis received a single payment of $23,866 in 2025, indicating a significant but isolated financial interaction. The entire payment originated from Roche/Genentech, suggesting a strong relationship with this specific pharmaceutical company. The payment was categorized as 'speaking,' implying an engagement related to educational or promotional activities.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Patricia Davis is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Patients should be aware that their doctor may receive payments from pharmaceutical companies for various services, and it's always a good idea to discuss any potential conflicts of interest. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Patricia Davis Compares to Other Oncology Physicians

Oncologists in Dallas, TX, typically have varied payment profiles, but a single large payment from one company is less common than multiple smaller payments from diverse sources.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Patricia Davis in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Roche/Genentech$23,865.50speakingN/A2025-11-22Not Assessed

Frequently Asked Questions About Dr. Patricia Davis's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Patricia Davis received?

Patricia Davis has received a total of $23.9K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Patricia Davis taking too much pharma money?

Patricia Davis has received $23.9K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Oncology), the types of payments, and how they compare to peers. The largest payment category is speaking ($23.9K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Patricia Davis?

The top pharmaceutical companies paying Patricia Davis are: Roche/Genentech ($23.9K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Patricia Davis receive?

Patricia Davis's payments by type: speaking: $23.9K.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Patricia Davis's payments compare to other Oncology doctors?

To compare, look at the total amount ($23.9K), number of payments (1), and the types of payments received. Oncology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Patricia Davis's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1144974276). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Patricia Davis's pharma payment profile?

The doctor's payment profile is highly concentrated, with 100% of the total amount coming from a single company. Patricia Davis has received $23.9K in total pharma payments.

How does Patricia Davis compare to peers in Oncology?

Oncologists in Dallas, TX, typically have varied payment profiles, but a single large payment from one company is less common than multiple smaller payments from diverse sources.

Are Patricia Davis's pharma relationships typical for Oncology?

The single payment of $23,866 is substantial, representing the entirety of the disclosed payments.

What should patients of Patricia Davis know about these payments?

Patients should be aware that their doctor may receive payments from pharmaceutical companies for various services, and it's always a good idea to discuss any potential conflicts of interest.

What patterns are visible in Patricia Davis's payment history?

The data shows a payment in 2025, which may reflect recent or future-dated disclosures.

Understanding This Doctor Payment Report

This transparency report for Dr. Patricia Davis is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Patricia Davis's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Patricia Davis and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.